Ziconotide (Prialt)

FDA-approved context Neuroprotection 3 sources

Ziconotide, marketed as Prialt, is a synthetic equivalent of a naturally occurring conopeptide found in the venom of the marine cone snail Conus magus. It is a potent, non-opioid analgesic that works by blocking N-type voltage-gated calcium channels in the spinal cord, effectively interrupting pain signal transmission. Research and clinical use have established its efficacy for severe, refractory chronic pain when administered intrathecally.

01Dosing reference

Amount

Initial dose of 2.4 mcg/day, titrated up to a maximum of 19.2 mcg/day

Frequency

Continuous infusion

Cycle

Ongoing chronic therapy via programmable microinfusion pump

Reference figures, not a recommendationThese values reflect amounts described in the literature and vendor documentation this database indexes. Use the reconstitution calculator to convert them into syringe units.

02Mechanism of action

N-Type Calcium Channel Blockade

Ziconotide selectively binds to and blocks N-type voltage-gated calcium channels (N-VGCCs) located on the primary nociceptive (pain-sensing) afferent nerves in the dorsal horn of the spinal cord.

Inhibition of Neurotransmitter Release

By blocking calcium influx into the nerve terminals, it prevents the release of pro-nociceptive neurotransmitters such as glutamate, calcitonin gene-related peptide (CGRP), and substance P.

Analgesic Effect

The interruption of these pain signaling pathways results in profound analgesia without the tolerance and addiction risks associated with opioid receptors.

03Human evidence

Significant reduction in Visual Analog Scale of Pain Intensity (VASPI) scores in patients with severe chronic pain.

Demonstrated in multiple randomized, double-blind, placebo-controlled trials in patients refractory to systemic analgesics or intrathecal morphine.

Lack of tolerance development and absence of withdrawal symptoms upon discontinuation.

Observed in long-term open-label extension studies, distinguishing it from opioid-based therapies.

04Preclinical evidence

Potent antinociceptive effects in models of acute, persistent, and neuropathic pain.

Demonstrated in rodent models using formalin tests and nerve ligation models, showing efficacy superior to morphine in certain neuropathic pain states.

Reversibility of calcium channel blockade.

In vitro electrophysiological studies on rat dorsal root ganglion neurons showed that the blockade of N-type calcium channels is reversible upon washout.

05What is known vs. unknown

Reasonably established

Ziconotide is a synthetic version of ω-conotoxin MVIIA from the venom of the Conus magus marine snail.
It is FDA-approved for severe chronic pain and is administered exclusively via intrathecal infusion.
It does not bind to opioid receptors, meaning it does not cause opioid-like respiratory depression, tolerance, or addiction.
Common side effects include dizziness, nausea, confusion, and memory impairment.
It has a narrow therapeutic window and requires careful titration to minimize severe psychiatric and neurological adverse events.

Unknowns & limits

The exact mechanisms underlying its severe psychiatric side effects (such as hallucinations and psychosis) are not fully understood.
Its use is limited by the requirement for an intrathecal pump, making it invasive and unsuitable for general outpatient use.
Long-term cognitive impacts of continuous N-type calcium channel blockade remain an area of ongoing observation.

06Safety & regulatory context

Regulatory statusZiconotide (Prialt) is FDA-approved for the management of severe chronic pain in patients requiring intrathecal therapy. It carries a Black Box Warning for severe psychiatric symptoms and neurological impairment, including hallucinations, paranoid reactions, hostility, delirium, psychosis, and manic reactions. It is contraindicated in patients with a pre-existing history of psychosis. Due to its route of administration, there are also risks associated with the intrathecal pump system, such as meningitis. It is not a controlled substance and has no known potential for abuse or dependence.

07Compared with Morphine (Intrathecal)

Ziconotide (Prialt) vs. Morphine (Intrathecal)

Key difference

Ziconotide blocks N-type calcium channels and does not cause tolerance or physical dependence, whereas morphine binds to mu-opioid receptors and is associated with tolerance, dependence, and respiratory depression.

When researchers discuss each

Morphine is often discussed as a first-line intrathecal analgesic due to familiarity and cost, while Ziconotide is discussed as a non-opioid alternative for patients who are refractory to or intolerant of intrathecal opioids.

08Glossary

Intrathecal (IT) Administration

Delivery of a drug directly into the cerebrospinal fluid within the spinal canal, bypassing the blood-brain barrier.

N-type Voltage-Gated Calcium Channels (N-VGCCs)

Specific ion channels found in nerve cells that regulate the release of neurotransmitters involved in pain signaling.

Conopeptide

A type of biologically active peptide found in the venom of marine cone snails, often targeting specific ion channels or receptors.

Nociceptive

Relating to the perception or sensation of pain.

09Knowledge check

Q1What is the primary mechanism of action of Ziconotide?

Q2Which of the following is a significant contraindication for the use of Ziconotide?

Q3Which statement best reflects a documented limitation of ziconotide use described in the dossier?

Q4According to the dossier, how do researchers typically frame comparisons between ziconotide and intrathecal morphine?

Q5Which regulatory or safety statement about ziconotide is supported by the dossier?

10Sources

More in Neuroprotection

See all

Cerebrolysin

Neuroprotection

Human clinical

Cerebrolysin is a complex mixture of low-molecular-weight peptides and amino acids derived from purified porcine brain tissue. Research indicates it mimics the action of endogenous neurotrophic factors, promoting neuroprotection, neurogenesis, and synaptic plasticity. It has been extensively studied and utilized in clinical settings for stroke recovery, traumatic brain injury, and neurodegenerative conditions like Alzheimer's disease.

5-50 mL per day depending on the severity of the condition (e.g., 5 mL IM for mild cognitive issues, up to 50 mL IV for acute stroke)

Pinealon

Neuroprotection

Early human

Pinealon is a synthetic tripeptide (Glu-Asp-Arg) designed to act as a peptide bioregulator for the brain and central nervous system. Research suggests it interacts directly with DNA to regulate gene expression, offering neuroprotective effects, improving cognitive function, and reducing oxidative stress in brain cells.

1-2 mg per day (SubQ) or 10-20 mg per day (Oral)

ARA-290 (Cibinetide)

Neuroprotection

Human clinical

ARA-290, also known as Cibinetide, is an engineered peptide derived from erythropoietin (EPO) that selectively activates the innate repair receptor (IRR) without stimulating red blood cell production. Research has primarily focused on its potential to reduce inflammation, promote tissue repair, and alleviate neuropathic pain, particularly in conditions like sarcoidosis and diabetic neuropathy.

4 mg/day

Research and educational use onlyNothing on this site is medical advice, a prescription, or a recommendation for human use. Compounds documented here are research chemicals. Consult a qualified clinician before making any health decision.